Orexin A, a hypothalamic neuropeptide, regulates food intake and sleep-wake cycle by binding to orexin receptor 1. Besides brain, orexin A and orexin receptor 1 are also present in peripheral organs. In our earlier studies, localization and expression of orexin A and orexin receptor 1 have been shown in adult mouse testis, and further their role in testicular development in neonatal mouse was also demonstrated. In this study, role of orexin A and orexin receptor 1 in the testis of adult mouse by blocking binding of orexin A to orexin receptor 1 using an orexin receptor 1 antagonist, SB-334867, was investigated under in vivo and ex vivo conditions. Mice were given a single bilateral intratesticular injection of the antagonist at doses of 4 and 12 lg/mouse and were sacrificed 24 h post-injection. The antagonist treatment caused degenerative changes in the seminiferous tubules in the testis and also caused alterations in steroidogenesis, with a concomitant decrease in the level of testosterone (T) and an increase in the level of 17b-estradiol (E 2 ) in serum and in testis. Further, expressions of SF1, StAR, P450scc and 17b-HSD were downregulated, while the expressions of 3b-HSD and P450arom were upregulated in antagonist-treated mice compared with controls. Also, the oxidative stress in the testis was increased in treated mice. In ex vivo study, antagonist treatment to the testis caused a marked decrease in the level of T and an increase in the level of E 2 in the media, accompanied by downregulated expression of SF1, StAR, P450scc and 17b-HSD and an upregulation in the expression of 3b-HSD and P450arom, indicating a direct role of orexin A in regulation of testicular steroidogenesis. The results of ex vivo study supported the findings of in vivo study. In conclusion, the results suggest potential involvement of orexin A and orexin receptor 1 in regulation of steroidogenesis and spermatogenesis in the testis of adult Parkes mice.
INTRODUCTION
Orexins (OXs) known also as hypocretins are the hypothalamic neuropeptides consisting of orexin A (OXA/hypocretin 1) and orexin B (OXB/hypocretin 2), and they modulate their actions via two G-protein-coupled receptors, orexin 1 receptor (OX1R) and orexin 2 receptor (OX2R), respectively (de Lecea et al., 1998; Sakurai et al., 1998) . The OX1R is highly selective for OXA, while OX2R allows binding of both orexins with similar affinity (Karteris & Randeva, 2003) . The orexin-producing neurons are located in lateral hypothalamic area, in perifornical area and in posterior hypothalamus (Sakurai & Mieda, 2011) , while the orexin receptors are found throughout the central nervous system (Trivedi et al., 1998; Marcus et al., 2001) . Orexins and their receptors are involved in the regulation of food intake, energy homoeostasis, sleep-wake cycle, drug addiction and in autonomic functions (Sakurai & Mieda, 2011; Xu et al., 2013; de Lecea & Huerta, 2014) . Besides their distribution throughout the brain (Leonard & Kukkonen, 2014) , orexins and their receptors are also found in peripheral tissues such as intestine, pancreas, adrenal, kidney, adipose tissue and in reproductive tracts (Kirchgessner & Liu, 1999; Johren et al., 2001; Nakabayashi et al., 2003; Silveyra et al., 2007a,b) . Expressions of OXA and OX1R have also been demonstrated in rat ovaries, testes and in principal cells of epididymis and in urethra-prostatic complex and vestibular glands of cattle (Johren et al., 2001; Barreiro et al., 2004 Barreiro et al., , 2005 Russo et al., 2008; Pavone et al., 2009; Tafuri et al., 2009 Tafuri et al., , 2010 Assisi et al., 2012) . Further, expressions of OXA and OXB have also been reported in porcine ovary at different stages of oestrous cycle, and these orexins are shown to play a role in ovarian steroidogenesis (Nitkiewicz et al., 2014) . It is also reported that OXA may modulate steroidogenesis in the porcine uterus during early pregnancy and oestrous cycle (Kiezun et al., 2017) .
Reports suggest that OXA participates in the regulation of steroidogenesis in rat testis (Barreiro et al., 2004 (Barreiro et al., , 2005 Assisi et al., 2012) . However, the mechanism(s) as to how OXA regulates testicular steroidogenesis and the physiological significance of OXA binding to OX1R in the testis have so far not been well evaluated. In our earlier study, we have reported the role of OXA and its receptor (OX1R) with reference to testicular development in neonatal mice (Joshi & Singh, 2016) . Further, we have also demonstrated the presence of OXA and OX1R in mouse testis during different stages of postnatal development, with their maximal expression at adult stage (Joshi & Singh, 2017) . The results of our latter study revealed strong immunopositive signals for both OXA and OX1R primarily in the Leydig cells, Sertoli cells, spermatogonia and in spermatocytes, suggesting possible involvement of OXA and OX1R in regulation of testicular functions in adult mouse. To obtain a better insight into the role of OXA and OX1R in regulation of testicular functions in adult mice, binding of OXA to OX1R in the testis was blocked using an OX1R antagonist, SB-334867. The effect of the antagonist treatment on steroidogenesis and spermatogenesis in the testis was examined; expressions of various steroidogenesis-related factors, activities of steroidogenic enzymes, and serum and intratesticular levels of testosterone and 17b-estradiol were evaluated. Further, oxidative stress in the testis was also assessed. In addition, an ex vivo experiment was performed to examine the direct role of OXA in regulation of testicular steroidogenesis.
MATERIALS AND METHODS

Antibodies and chemicals
The OX1R antagonist, SB-334867, was purchased from Tocris Bioscience, Bristol, UK), while 2 hydroxy-propyl-ß cyclodextrin (encapsin), penicillin and streptomycin sulphate were purchased from Sigma-Aldrich, St. Louis, MO, USA and polyvinylidene difluoride (PVDF) membrane from Merck Millipore, Bangalore, India. Trizol reagent and DNA ladder marker were purchased from Invitrogen, Carlsbad, CA, USA and New England BioLabs, Hitchin, UK, respectively. The cDNA synthesis kit, PCR master mix kit (2X) and enhanced chemiluminescence (ECL) reagents kit were purchased from Thermo Fisher Scientific, Rockford, IL, USA. All primers were obtained from Eurofins Genomics India Ltd., Bangalore, India, while ELISA kits for testosterone (T) and 17b-estradiol (E 2 ) were purchased from DiaMetra, Segrate, Italy. All other chemicals used in this study were of analytical grade and purchased from HiMedia Laboratories, Mumbai, India or E. Merck India Ltd., Mumbai, India unless stated otherwise. The details of primer pairs and PCR conditions and antibodies used are summarized in Tables 1 and 2 , respectively.
Animals
Adult (age 12-14 weeks) male Parkes (P) strain mice were used in the present investigation, and we have been using P mice as animal model (Joshi & Singh, 2016 Sarkar & Singh, 2017a) . Mice (35-40 g) from a closed and randomly bred colony maintained in the animal house of the Department of Zoology, Institute of Science, Banaras Hindu University were used in this study. Animals were housed under strict hygienic conditions in a well-ventilated room at 23 AE 2°C with a 12 h photoperiod and relative humidity of 50 AE 20%. Mice were housed in polypropylene cages (450 mm 9 270 mm 9 150 mm) with dry rice husk as bedding material, and they were fed on pellet food (Amrut Laboratory Animal Feeds, Pune, India) and drinking water ad libitum. Animals were maintained according to guidelines of the Animal Ethics Committee of the Banaras Hindu University (No. Dean/13-14/CAEC/340; dated, 27-07-2013) as per approval of committee for the purpose for control and supervision of experimental animals (CPCSEA), Government of India (No. 1802/G0/ Re/S/15/CPCSEA).
Experimental design I (in vivo study)
Selection and preparation of doses
Role of OXA in adult mouse testis was studied by blocking the binding of OXA to OX1R in the gonad, using a selective non-peptide OX1R antagonist, SB-334867, and the antagonist was dissolved in vehicle which consisted of 10% (w/v) encapsin and 1% (v/v) dimethyl sulfoxide (Joshi & Singh, 2016) . Doses of OX1R antagonist were selected on the basis of a preliminary dose-response study conducted by us in P mice. Briefly, pilot experiments were carried out to determine the doses and durations of OX1R antagonist treatment. Serum and intratesticular levels of testosterone (T) and estradiol (E 2 ) as well as testis histopathology were considered as endpoint criteria for reproductive parameters, while serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and liver histopathology were taken as toxicological endpoints. Doses of the antagonist were selected based on the study of Allen et al. (2011) , where neuropeptide Y at a dose of 5 lg/kg was injected directly into rat testis to see its effect on T production. In our study, 2, 4, 8, 12 and 16 lg of SB-334867 were injected directly into mice testis to see the effect of the antagonist on testicular steroidogenesis and spermatogenesis at 6, 12, 24, 48 and 72 h post-treatment. Based on reproductive and toxicological outcomes, 4 and 12 lg doses of OX1R antagonist were selected for a period of 24 h.
Treatment
Mice were weighed and randomly allocated to three (I-III) groups, each comprising 15 individuals (n = 15). Mice in group I were administered a single bilateral intratesticular (i.t.) injection of vehicle (25 lL per testis), while those in groups II and III were administered (i.t.) 4 and 12 lg of the antagonist, respectively, in a similar way. Both doses of the antagonist were prepared in 50 lL of vehicle for each mouse and injected into each testis at the rate of 25 lL totalling to 50 lL/mouse (Gerendai et al., 1993; Rivier, 2008) . Intratesticular injections were given following the protocol of Qin et al. (2016) . Briefly, mice were anaesthetized under mild ether anaesthesia, the testes were gently pushed into the scrotum from the abdominal cavity and the scrotum was then disinfected by rubbing alcohol. The testis was then fixed between the left forefinger and thumb so that the longitudinal axis of the testis remained parallel to the left forefinger and thumb with the testicular tail outside the body, and the injection was given from the testicular tail along the long axis of the testis. OX1R antagonist (SB-334867) was injected directly into the testis using a sterile infant transfusion needle held with the right hand. Preliminary studies conducted with Evans Blue indicated that 466 Andrology, 2018, 6, 465-477 this protocol was consistent with wide spread disbursement of the injection volumes (Allen et al., 2011) .
Autopsy, and blood and tissue collection
Animals from each group were sacrificed by decapitation under mild ether anaesthesia 24 h post-injection, after recording their final body weights. Blood from trunk region was collected, and serum was separated and stored at À20°C until further use. Testes were randomly excised from either the left or the right side of five mice in each group for histological studies, while testes from the contralateral sides of the above five mice and both testes from the remaining mice were excised, blotted free of blood, weighed and kept frozen at À80°C until processed for RT-PCR, immunoblot and biochemical analyses.
Experimental design II (ex vivo study)
Selection of optimum doses and duration
To understand the direct role of OXA in testes of adult mice, an ex vivo experiment was performed. To the best of our knowledge, we did not find a report dealing with the use of OX1R antagonist (SB-334867) under ex vivo conditions in mice testis. The doses of the antagonist used in this study were based on a pilot study under ex vivo conditions. Ours is the first report where we have used this antagonist to evaluate the role of OXA in testis development in neonatal mice (Joshi & Singh, 2016) . The 0.1 and 4 lg/mL media doses of the antagonist showed good results. Therefore, the same doses were selected in the present investigation under ex vivo conditions.
Similarly, for deciding the incubation time of culture, preliminary experiments were performed where adult mice testis slices were kept in media with the antagonist for different durations such as 6, 12, 18, 24, 48 and 72 h. At the incubation time of 24 h at 37°C, the pH, colour and fluidity of the media were not changed indicating that the culture was healthy and not contaminated for 0.1 and 4 lg/mL media doses. In addition, testes appeared healthy and did not show any sign of abnormality during ex vivo study after 24 h. The present ex vivo study did not exhibit any toxic effect, and this was ascertained by LDH cytotoxicity assay in the media (data not presented) (Legrand et al., 1992) .
Treatment
Fifteen adult male mice were sacrificed under ether anaesthesia, and their testes were immediately excised and cut into approximately equal parts (three slices/testis and weight of each slice was 25 AE 2 mg). These slices were incubated in 1 mL complete media consisting of 1 : 1) supplemented with penicillin (100 U/mL) and streptomycin sulphate (100 U/mL) at 37°C in a humidified atmosphere with 95% air and 5% CO 2 to maintain a pH at 7.4 (Joshi & Singh, 2016) . After preincubation for 1 h, the media were replaced with 1 mL fresh media containing vehicle and two doses of SB-334867, 0.1 and 4.0 lg/mL. After 24 h incubation, testes slices were collected, pooled and kept frozen at À80°C until further use, while the media were stored at À20°C for hormone assay. The activities of 3b-and 17b-HSD enzymes and the expressions of SF1, StAR, P450scc, 3b-and 17b-HSD and P450arom at transcript and protein levels were assessed in testicular samples. Treatment and control groups were run in triplicate and the experiment was repeated two times.
Histopathology of testis
For histological study, testes were fixed in Bouin's solution for 24 h, dehydrated in ascending series of ethanol, cleared in benzene and embedded in paraffin. Tissues were sectioned at 6 lm using a microtome (Leica, Wetzlar, Germany), and the sections were stained with periodic acid-Schiff and counterstained with haematoxylin. The stained sections were then examined under a Leica light microscope equipped with digital camera (Leica EC3, Wetzlar, Germany). Stages of spermatogenesis in mouse testis were identified according to the criteria of Russell et al. (1990) . Diameter of the seminiferous tubules and height of the germinal epithelium were measured in stage VII round or slightly oblique seminiferous tubules (n = 10) (Verma & Singh, 2014) . This stage of the spermatogenic cycle was chosen because it is the most frequent stage of spermatogenesis and exhibits the largest mean diameter (Wing & Christensen, 1982) . For determination of percentage of affected seminiferous tubules, all the tubules in a randomly selected section of the testis from five mice in each group were counted (Singh & Rath, 1990) , and the tubules considered affected were those that showed degenerative changes such as intraepithelial vacuolation, thinning of germinal epithelium, degeneration of germ cells and exfoliation of germ cells.
Hormone assay (testosterone and 17b-estradiol)
Levels of testosterone (T) and 17-b estradiol (E 2 ) in serum, in medium and in the testis (intratesticular) were measured in this study by ELISA. The protocol of Jeyaraj et al. (2005) with minor modifications (Sarkar & Singh, 2017b) was followed for the extraction of T and E 2 from testicular samples. Briefly, whole testis was homogenized in 1 mL of phosphate-buffer saline (PBS) by sonication. The homogenate (~1 mL) was then extracted with diethyl ether, evaporated and resuspended in PBS for assay of hormones.
The serum, media and testicular samples as above were used for the estimation of T and E 2 levels as per manufacturer's instructions, using a highly sensitive and specific commercial ELISA kit. The sensitivity of the assays for T and E 2 was 0.07 ng/ mL and 8.68 pg/mL, respectively. All samples were quantified in a single assay with intra-and inter-assay coefficient of variations being 5.8 and 10.5%, respectively for T, while the intra-and interassay coefficient of variations for E 2 were 9 and 10%, respectively. The ELISA kit for E 2 was shown to possess 100% cross-reactivity for 17b-estradiol. The experiments were repeated thrice.
Steroidogenic enzymes activities
Activities of 3b-and 17b-hydroxysteroid dehydrogenase (3b-and 17b-HSD) were measured in the testis according to the methods of Talalay (1962) and Jarabak et al. (1962) , respectively, with minor modifications (Sarkar et al., 2016) . The basis of the assay is that the reaction velocity of the enzymes is measured as an increase in absorbance at 340 nm, resulting from the reduction of NAD. One unit of the enzyme activity is the amount causing a change in absorbance of 0.001/min at 340 nm.
Briefly, 10% tissue homogenate was prepared in buffer consisting 20% spectroscopic grade of glycerol containing 5 mM potassium phosphate and 1 mM EDTA. The homogenate was centrifuged at 10,000 g for 30 min at 4°C, and the supernatant was used for enzyme assay.
3b-HSD activity was measured by mixing 125 lL of the supernatant with 125 lL of 100 lM sodium pyrophosphate buffer (pH 8.9), 5 lL ethanol containing 15 lg DHEA (Sigma) and 120 lL of 25 mg% BSA (GeNei, Bangalore, India). Enzyme activity was measured after addition of 25 lL of 0.5 lM NAD to the mixture in a spectrophotometer (Chemito Spectrascan UV2700; Thermo Scientific, Waltham, MA, USA) at 340 nm against a blank (without NAD). One unit of enzyme activity was the amount causing a change in absorbance of 0.001/min at 340 nm.
Likewise, 17b-HSD activity was measured by mixing 125 lL of the supernatant with 125 lL of 440 lM sodium pyrophosphate buffer (pH 10.2), 5 lL ethanol containing 0.3 lM testosterone (Sigma) and 120 lL of 25 mg% BSA. Enzyme activity was measured after addition of 25 lL of 0.5 lM NAD to the mixture in a spectrophotometer at 340 nm against a blank (without NAD). One unit of enzyme activity was the amount causing a change in absorbance of 0.001/min at 340 nm. The experiments were repeated thrice.
Evaluation of oxidative stress parameters
The level of lipid peroxidation (LPO) and the activities of superoxide dismutase (SOD) and catalase in the testis were determined according to the methods of Ohkawa et al. (1979) , Das et al. (2000) and Aebi (1974) , respectively, with minor modifications (Sarkar & Singh, 2017a) . The experiments were repeated thrice.
Semi-quantitative RT-PCR analysis
Procedure for total RNA isolation from testicular samples and their subsequent cDNA synthesis have been described in detail in our earlier publication (Joshi & Singh, 2016) . The cDNAs obtained were used as a template for subsequent PCR amplification using a commercially available PCR master mix kit. In brief, reaction mixtures (25 lL) for PCR were assembled using l lL cDNA template, 20 pM of each forward and reverse primers, 0.05 U/lL Taq DNA polymerase, 0.4 mM of dNTPs, and 4 mM MgCl 2 in 2X PCR buffer in a Veriti thermal cycler (Applied Biosystems, Foster City, CA, USA). PCR consisted of a first denaturing cycle at 95°C for 10 min, followed by a variable number of cycles of amplification defined by denaturation at 95°C for 30 sec, annealing for 45 sec and extension at 72°C for 45 sec. A final extension cycle of 72°C for 7 min was included. Annealing temperature for each of the target transcripts is indicated in Table 1 . Finally, the amplified PCR products were analysed by electrophoresis on 2% agarose gels containing ethidium bromide and visualized in a gel documentation system (Bio-Rad Labs., Hercules, CA, USA). Intensity of RT-PCR signals was quantified by densitometric scanning using IMAGEJ analysis system (NIH, Bethesda, MD, USA). PCR product of b-actin was used as an internal control and values of the specific targets were normalized to those of internal controls to express arbitrary units of relative expression and each of the RT-PCR was performed thrice. Mouse-specific primer sequences for the genes of interest, product size, annealing temperature, numbers of cycles used in this study are presented in Table 1 . Immunoblot analysis of testicular proteins The extraction and immunoblot analysis of testicular protein were performed following the protocol described by Sarkar et al. (2016) . Briefly, protein was extracted from the testis and its concentration was determined by Lowry's method (Lowry et al., 1951) . Equal amount of proteins (50 lg) was resolved on 10-12% SDS-PAGE using mini gel system (GeNei, Bangalore, India) and transferred to PVDF membranes (0.45 lm). The membranes were incubated in blocking buffer consisting of 5% (w/v) non-fat dry milk powder in 0.1% (v/v) Tween-20 and tris-buffered saline (TBS-T) for 2-3 h at room temperature. Thereafter, the membranes were incubated with primary antibodies against SF1, StAR, P450scc, 3b-HSD, 17b-HSD and P450arom at 4°C for overnight. Details of all the antibodies and their dilutions used in this study are described in Table 2 . Antibodies were diluted in TBS-T containing 2% (w/v) non-fat dry milk powder. Next day, membranes were washed with TBS-T thrice for 10 min each and were incubated with HRPconjugated secondary antibodies (diluted in TBS-T containing 2% (w/v) non-fat dry milk powder) for 2-3 h at room temperature. After washing the membranes with TBS-T thrice for 15 min each, the signals were detected using ECL reagents kit on X-ray film. The resulting immunoreactive bands were quantified by IMAGEJ software (NIH, Bethesda, MD, USA). To monitor equal loading of gel lanes, the blots were stripped by incubation for 30 min at 70°C with a solution containing 2% SDS, 100 lM b-mercaptoethanol in 62.5 mM Tris-HCl, pH 6.8 and re-probed with b-actin antibody. Blot for each protein was repeated three times.
Statistical analysis
All data (mean AE SEM), except for body weight, were analysed by one-way analysis of variance (ANOVA) followed by Duncan's multiple range test using SPSS 16.0 software for comparison of means. Body weight data were, however, analysed by t-test. Differences were considered significant at p < 0.05.
RESULTS
Body and testis weight
No significant differences were found between the initial and final body weights of OX1R antagonist-treated mice and controls (Table 3) . However, a significant decrease was noted in the weight of the testis in mice treated with both the doses of the antagonist compared with controls (Table 3) .
Testicular histology
The testes of vehicle-treated controls (Fig. 1A ) exhibited normal histological features in nearly all the seminiferous tubules, except in a few (9.10%) in which the tubules showed loosening of germinal epithelium or intraepithelial vacuolation. However, testes in antagonist-treated mice at both doses showed marked degenerative changes in the seminiferous tubules, although the changes were not uniform as both affected (4 lg, 28.6%; 12 lg, 35.3%) and normal (4 lg, 71.4%; 12 lg, 64.7%) tubules were seen in the same sections. The degenerative changes observed in the tubules in testes of treated mice were similar, so they are described together. In general, the affected seminiferous tubules showed intraepithelial vacuolation, thinning of germinal epithelium with marked depletion of germ cells, degeneration of germ cells and exfoliation of germ cells (Fig. 1B-D) . Further, significant reductions in height of the germinal epithelium and in the diameter of the seminiferous tubules were also noted in antagonist-treated mice compared with controls (Fig. 1E) . The percentage of affected seminiferous tubules was also significantly high in testes of treated mice in comparison with controls (Table 3) .
T and E 2 levels
A significant decrease in both serum and intratesticular levels of T (Fig. 2A,B) and a significant increase in serum and Figure 2 Hormones assay and steroidogenic enzymes activities. (A and B) T and E 2 levels in serum and in testis after OX1R antagonist treatment (4 and 12 lg/mouse); and (C) activities of steroidogenic enzymes (3b-and 17b-HSD) in the testis after the same treatment as in A and B. Note a significant decrease in the level of T and an increase in E 2 level in antagonist-treated mice compared with controls (A and B). Also, note a significant decrease in 17b-HSD enzyme activity in antagonist-treated mice compared with controls, although no change is noted in 3b-HSD activity (C). Values are mean AE SEM (n = 5). *Significantly different from controls (p < 0.05) by ANOVA followed by Duncan's multiple range test. [Colour figure can be viewed at wileyonlinelibrary.com]. Figure 3 Hormones assay and steroidogenic enzymes activities under ex vivo conditions. (A) Levels of T and E 2 in media and (B) activities of testicular steroidogenic enzymes (3b-and 17b-HSD) after ex vivo treatment with OX1R antagonist to the testis at doses of 0.1 and 4 lg/mL media compared with controls. Values are mean AE SEM (n = 5). *Significantly different from controls (p < 0.05) by ANOVA followed by Duncan's multiple range test. [Colour figure can be viewed at wileyonlinelibrary.com] intratesticular levels of E 2 ( Fig. 2A,B) were noted in antagonisttreated mice compared with controls. The serum level of T in control group was 5.52 AE 0.33 ng/mL, while the same was 3.84 AE 0.16 and 2.42 AE 0.19 ng/mL in 4 and 12 lg antagonisttreated dose groups, respectively ( Fig. 2A) (Fig. 2B) . The serum level of E 2 in control group was 23.6 AE 1.09 pg/mL, while the same was 31.7 AE 1.30 and 31.2 AE 1.80 pg/mL in 4 and 12 lg antagonist-treated groups of mice, respectively ( Fig. 2A) . However, intratesticular level of E 2 in control group was 808.18 AE 31.02 pg/g tissue, while this was 1440.55 AE 41.88 and 1550.22 AE 49.20 pg/g tissue in 4 and 12 lg antagonist-treated groups, respectively (Fig. 2B) .
The results of ex vivo experiment for hormones (T and E 2 ) level in the media followed a similar pattern (Fig. 3A) . The level of T in media of control group was 6.62 AE 0.39 ng/mL, while the same was 2.90 AE 0.14 and 3.34 AE 0.12 ng/mL in 0.1 and 4 lg antagonist/mL media dose groups, respectively (Fig. 3A) . On the other hand, the level of E 2 in the media of control group was 19.9 AE 0.74 pg/mL, while this was 33.14 AE 1.18 and 31.2 AE 0.62 pg/mL in 0.1 and 4 lg antagonist/mL media dose groups, respectively (Fig. 3A) .
3b-and 17b-HSD enzymes activities
A significant decrease in the activity of 17b-HSD was noted in testes of antagonist-treated mice compared with controls, but there was no change in the activity of this enzyme under ex vivo condition. The 17b-HSD enzyme activity in testicular samples of control group was 34.3 AE 0.64 Unit/mg tissue/h, while this was 26.1 AE 0.42 and 19.8 AE 0.54 Unit/mg tissue/h in 4 and 12 lg antagonist/mouse dose groups, respectively (Fig. 2C) . On the other hand, however, under ex vivo condition, the enzyme activity was 7.25 AE 0.71 Unit/mg tissue/h in testicular samples of control group, while the same was 7.29 AE 0.60 and 7.39 AE 0.76 Unit/mg tissue/h in 0.1 and 4 lg antagonist/mL media dose groups, respectively (Fig. 3B) .
In vivo study, the activity of 3b-HSD in the testis was not affected after antagonist treatment in comparison with controls ( Fig. 2C) , while a marked increase in testicular 3b-HSD activity was noted after antagonist treatment under ex vivo condition compared with controls (Fig. 3B) . Under in vivo condition, 3b-HSD enzyme activity in testicular samples of control group was 34.1 AE 0.52 Unit/mg tissue/h, while the same was 35.46 AE 0.63 and 32.24 AE 1.29 Unit/mg tissue/h in 4 and 12 lg antagonisttreated dose groups, respectively (Fig. 2C) . However, under ex vivo condition, the enzyme activity was 9.46 AE 0.40 Unit/mg tissue/h in testicular samples of control group, while the same was 11.26 AE 0.94 and 12.7 AE 0.56 Unit/mg tissue/h in 0.1 and 4 lg antagonist/mL media dose groups, respectively (Fig. 3B) .
Lipid peroxidation and antioxidant enzymes activities
The level of LPO was markedly increased in testis of antagonist-treated mice at both doses compared with controls. However, the activities of antioxidant enzymes (SOD and catalase) were significantly decreased in the testis of antagonist-treated mice with respect to controls (Table 4) .
RT-PCR analyses of testicular steroidogenic genes
The mRNA levels of SF1, StAR, P450scc and 17b-HSD were significantly decreased in the testis of antagonist-treated mice at both doses compared with controls (Fig. 4A,B) . The expression of SF1, StAR, P450scc and 17b-HSD mRNAs was decreased up to 14.8, 59.9, 39.1 and 11.7%, respectively in lower dose (4 lg) of antagonist-treated mice, while the same in the above sequence was decreased by 48.7, 73.2, 65.5 and 30.9%, respectively in higher dose (12 lg) group of antagonist-treated mice in comparison with controls (Fig. 4B) . On the other hand, treatment with 4 and 12 lg of the antagonist resulted in a significant increase in the relative expression levels of 3b-HSD mRNA by 10.9 and 45.9%, respectively, and by 52.7 and 68.5%, respectively for P450arom mRNA compared with controls (Fig. 4A,B) . 
Immunoblot analyses of testicular proteins
Immunoblot analysis revealed a significant downregulation in expression levels of SF1, StAR, P450scc and 17b-HSD (Fig. 5A,B) in testes of treated mice at both doses compared with controls. In mice treated with 4 lg antagonist, the relative expression levels of SF1, StAR, P450scc and 17b-HSD were decreased by 13.9, 46.2, 24.5 and 9.2%, respectively compared with controls (Fig. 5B) , while the same in the above sequence were decreased by 25.5, 68.3, 62 and 27.6%, respectively in mice treated with 12 lg of the antagonist in comparison with controls (Fig. 5B) . In contrast, a marked increase in expression levels of 3b-HSD and P450arom was noted in testes of mice treated with 4 lg of the antagonist and this increase was by 9.7 and 88.6%, respectively compared with controls (Fig. 5A,B) . Further, an increase in expression levels of 3b-HSD and P450arom in 12 lg group of antagonist-treated mice was noted by 6.5 and 71.2%, respectively with reference to controls (Fig. 5A,B) .
Ex vivo study: expression levels of steroidogenesis-related factors A significant decrease in the expression of SF1, StAR, P450scc and 17b-HSD at mRNA (Fig. 6A,B) and protein (Fig. 7A,B ) levels were noted 24 h after treatment with 0.1 and 4 lg of OX1R antagonist compared with controls. However, there was a significant increase in expression levels of 3b-HSD and P450arom at both doses of the antagonist compared with controls (see Figs 6A,B and 7A,B) .
The relative mRNA expression levels of SF1, StAR, P450scc and 17b-HSD were decreased by 43.1, 47.2, 41 and 20%, respectively at 0.1 lg dose, while the above in the same sequence were decreased up to 41.2, 75.2, 76.4 and 17.9%, respectively at 4 lg dose compared with controls (Fig. 6B) . Further, relative mRNA expressions of 3b-HSD and P450arom were upregulated by 15.7 and 65.4%, respectively at 0.1 lg dose and by 14.6 and 81.3%, respectively at 4 lg antagonist dose compared with controls (Fig. 6B) . The relative expressions of SF1, StAR, P450scc and 17b-HSD at protein level were downregulated by 17.7, 21, 9.1 and 28%, respectively at 0.1 lg dose and by 34.2, 37.4, 19.8 and 64 .5%, respectively at 4 lg dose treatment compared with controls (Fig. 7B) . Further, the relative expressions of 3b-HSD and P450arom were increased by 44 and 59.6%, respectively at 0.1 lg dose and by 24 and 78.8%, respectively at 4 lg dose with respect to controls (Fig. 7B) .
DISCUSSION
It is well-known that OXA performs its action through two Gprotein-coupled receptors, orexin 1 receptor (OX1R) and orexin 2 receptor (OX2R), respectively. The antagonist, SB-334867, used in the present study is selective for OX1R, so there is a minimal possibility of OXA binding to OX1R in the antagonist-treated mice. However, the possibility of OXA interaction with OX2R cannot altogether be ruled out, and further studies would be required to ascertain the role of OX2R under these conditions. The present results show that treatment with OX1R antagonist caused a marked reduction in testis weight accompanied by diverse degenerative changes in the seminiferous tubules. The observation of a marked decrease in the diameter of the seminiferous tubules and in the height of the germinal epithelium in testes of the antagonist-treated mice in this study is suggestive of the adverse effect of OX1R antagonist on spermatogenesis (D'Souza, 2004) . Further, the finding of a marked increase in the percentage of affected seminiferous tubules in testes of the antagonist-treated P mice compared with controls also lends support to the above contention. Testosterone is essential for the maintenance of spermatogenesis and male fertility (Smith & Walker, 2014) , and biosynthesis of this hormone in the testis requires expressions of several proteins such as SF1, StAR, P450scc, 3b-and 17b-HSD and 17a-hydroxylase (Val et al., 2003; O'Donnell et al., 2006) . In the present study, diminished level of testosterone after OX1R antagonist treatment may have been caused by downregulation in expression levels of SF1, StAR, P450scc and 17b-HSD in antagonist-treated mice compared with controls under both in vivo and ex vivo conditions. The present results show an inhibitory influence of OX1R antagonist treatment on T biosynthesis. Barreiro et al. (2004) have also reported Figure 7 Immunoblot analyses of steroidogenesis-related factors under ex vivo conditions. (A) Immunoblot analyses of steroidogenic markers (SF1, StAR, P450scc, 3b-HSD, 17b-HSD and P450arom) in the testes after ex vivo treatment with OX1R antagonist at doses of 0.1 and 4.0 lg/mL media. All protein expression levels were normalized relative to b-actin, loading control. (B) Densitometric data are presented as the mean of integrated relative density value (IRDV) AE SEM of triplicate blots. *Significantly different from controls (p < 0.05) by ANOVA followed by Duncan's multiple range test.
474 Andrology, 2018, 6, 465-477 a regulatory role of OXA in T secretion in rat testis. In the present study, it may be hypothesized that interference with binding of OXA to OX1R downregulates the expression of SF1, an indispensable transcription factor for the expression of all steroidogenic P450 genes (Morohashi et al., 1992) . Further, SF1 participates in expression of steroidogenic enzymes in adrenal cortex and gonads and is also able to modulate the cholesterol delivery to steroidogenic reactions and the expression of StAR protein (Val et al., 2003) . It is, therefore, likely that the decreased expression of SF1 after OX1R antagonist treatment may have downregulated the expression levels of StAR and P450scc in P mice in the present study. Thus, the inhibitory influence of OX1R antagonist on steroidogenesis-related factors as above in this study may altogether contribute to a decrease in T level in in vivo and ex vivo conditions. On the other hand, however, a significant increase was noted in expression level of 3b-HSD in antagonist-treated mice compared with controls, despite downregulated expression of SF1, which acts as a transcription factor for expression of this enzyme (Leers-Sucheta et al., 1997) . It is relevant to mention here that in addition to SF1, several other factors such as Dax-1, fetoprotein transcription factor, GATA4 and 6 and LH/hCG are also known to influence the transcription and activity of 3b-HSD (Rasmussen et al., 2013) . Kostic et al. (2011) have reported that androgenization to rat causes upregulation in expression and activity of 3b-HSD enzyme, despite decline in expression of steroidogenesis-related factors such as StAR and P450scc.
The results of the present study indicate a marked decrease in the activity of 17b-HSD in OX1R antagonist-treated mice compared with controls under in vivo condition, while the same was not altered under ex vivo condition. Further, the antagonist had no effect on the activity of 3b-HSD under in vivo condition, while the enzyme activity was increased under ex vivo condition. The discrepancies in enzyme activities under in vivo and ex vivo conditions may partly be attributed to the differences in biochemical constituents under the two assay conditions (Garcı a-Contreras et al., 2012). Besides, it is also technically difficult to completely mimic all the properties of cytosol under in vivo condition to that under ex vivo condition (Garcı a-Contreras et al., 2012) . One of the striking observations of the present study is that there was an increase in serum and intratesticular levels of E 2 accompanied by an increase in the expression of P450arom at both mRNA and protein levels, despite low level of testosterone in OX1R antagonisttreated mice compared with controls. It is difficult to offer an explanation for an increase in oestrogen level despite a decrease in testosterone level, while the latter serves as a substrate for E 2 . The finding of an increased expression of P450arom in the testis after antagonist treatment in the present study may have a contributory role to the increased level of E 2 . It is well-known that dehydroepiandrosterone (DHEA) is converted to androstenedione by 3b-HSD and/or to androstenediol by 17b-HSD in steroidogenic machinery (Payne & Youngblood, 1995) . On the basis of the present results, therefore, one may hypothesize that DHEA will rapidly be converted to androstenedione rather than to androstenediol because of an increase in the expression of 3b-HSD. Further, androstenedione is converted to testosterone by 17b-HSD and testosterone to estradiol by P450arom (Payne & Youngblood, 1995) . Thus, the increased expression of P450arom and a decreased expression of 17b-HSD after OX1R antagonist treatment may account for an increase in E 2 level and a decrease in T level. However, the exact reason(s) for an increase in E 2 level despite a decrease in T level remains unknown and requires further studies. It is well documented that the maintenance of spermatogenesis depends upon the delicate balance of the hypothalamus-pituitary-testis (HPT) axis and that the oestrogen administration or deprivation can affect HPT axis (O'Donnell et al., 2001) . Thus, any disturbance in E 2 level is likely to cause an imbalance in HPT axis, leading to an adverse effect on spermatogenesis (O'Donnell et al., 2001) . Reports also indicate that an excess level of E 2 has adverse effect on spermatogenesis (Bharti et al., 2013) . According to Barreiro et al. (2004) , E 2 administration in rat during neonatal period results in suppression of OX1R mRNA level in the testis at adulthood.
Lipids in the plasma membrane are one of the major targets of reactive oxygen species, which, in turn, causes LPO (de la Haba et al., 2013) . On the other hand, SOD and catalase are important members of the antioxidant defence system for rescue of cells from oxidative stress. Oxidative stress downregulates the steroidogenic activity of Leydig cells leading to altered testicular functions (Maneesh et al., 2005) . It is also suggested that the alterations in hormonal milieu in the testis lead to an increase in oxidative stress and germ cell apoptosis, resulting into suppression of spermatogenesis (Chaki et al., 2006) . In the present study, therefore, an increased oxidative stress in terms of increased LPO and decreased SOD and catalase activities after the antagonist treatment could result either from (i) the altered levels of T and/or E 2, or (ii) the direct effect of the antagonist treatment, or (iii) from a combined effect of both of the above (i and ii). The increased oxidative stress in the testis after the antagonist treatment is likely to be one of the causes that lead to impairment of spermatogenesis. A model diagram describing the effect of OX1R antagonist treatment on spermatogenesis in adult P mice in relation to testicular steroidogenesis and oxidative stress is depicted in Fig. 8 .
In conclusion, the results in P mice suggest that interference with binding of OXA to OX1R in the testis causes alterations in steroidogenesis, with a decrease in T level and an increase in E 2 level under both in vivo and ex vivo conditions. Further, the treatment also increased the level of LPO and decreased the activities of antioxidant enzymes (SOD and catalase) in the testis. Thus, an imbalance in hormonal levels and an increase in oxidative stress in the testis cause suppression of spermatogenesis. Therefore, it is hypothesized that the binding of OXA to OX1R in the testis helps in regulation of steroidogenesis and spermatogenesis in P mice.
